全文获取类型
收费全文 | 872篇 |
免费 | 33篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 26篇 |
妇产科学 | 5篇 |
基础医学 | 57篇 |
口腔科学 | 16篇 |
临床医学 | 43篇 |
内科学 | 148篇 |
皮肤病学 | 16篇 |
神经病学 | 54篇 |
特种医学 | 182篇 |
外科学 | 226篇 |
综合类 | 39篇 |
预防医学 | 20篇 |
眼科学 | 7篇 |
药学 | 20篇 |
中国医学 | 1篇 |
肿瘤学 | 49篇 |
出版年
2024年 | 1篇 |
2023年 | 5篇 |
2022年 | 13篇 |
2021年 | 11篇 |
2020年 | 7篇 |
2019年 | 10篇 |
2018年 | 15篇 |
2017年 | 15篇 |
2016年 | 9篇 |
2015年 | 16篇 |
2014年 | 17篇 |
2013年 | 25篇 |
2012年 | 41篇 |
2011年 | 40篇 |
2010年 | 37篇 |
2009年 | 34篇 |
2008年 | 40篇 |
2007年 | 29篇 |
2006年 | 33篇 |
2005年 | 37篇 |
2004年 | 20篇 |
2003年 | 16篇 |
2002年 | 21篇 |
2001年 | 16篇 |
2000年 | 22篇 |
1999年 | 15篇 |
1998年 | 27篇 |
1997年 | 43篇 |
1996年 | 32篇 |
1995年 | 26篇 |
1994年 | 19篇 |
1993年 | 18篇 |
1992年 | 12篇 |
1991年 | 8篇 |
1990年 | 11篇 |
1989年 | 15篇 |
1988年 | 17篇 |
1987年 | 19篇 |
1986年 | 21篇 |
1985年 | 14篇 |
1984年 | 10篇 |
1983年 | 6篇 |
1982年 | 11篇 |
1981年 | 14篇 |
1980年 | 13篇 |
1979年 | 2篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1976年 | 7篇 |
1975年 | 5篇 |
排序方式: 共有909条查询结果,搜索用时 0 毫秒
51.
Fleshner N 《The Canadian journal of urology》2005,12(Z1):14-7; discussion 94-6
Defining men at high risk for prostate cancer treatment failure and death continues to evolve. Identifying these men allows for better disease prognostication, patient decision treatment making and facilitates accrual for appropriate clinical trials. Men at traditional high risk for prostate cancer progression and death include men with advanced clinical stage, higher levels of PSA and Gleason pattern 4. Utilizing accepted methods of risk stratification including nomograms can aid in case identification. Softer risk factors such as obesity, race, socioeconomic status, and genetic polymorphisms are increasingly being studied. Ultimately high-throughput genomics will aid in identification of these men. 相似文献
52.
Essiac is a popular complementary and alternative medicine (CAM) that is utilized by many cancer patients in North America. Much anecdotal reporting exists about its cancer-fighting qualities, but so far no clinical trials have been preformed to validate those claims. We describe here the case of a 64-year-old man whose hormone-refractory prostate cancer responded well to Essiac tea. 相似文献
53.
54.
BACKGROUND: Treatment recommendations for localized prostate carcinoma are based on the patient's remaining life expectancy (RLE), which is influenced by age, comorbidity, and tumor grade. Previous studies have evaluated the influence of age and comorbidity, but to the authors' knowledge not RLE, on actual treatment decisions. METHODS: An age-stratified random sample of 347 patients was generated from a cohort of all patients with newly diagnosed prostate carcinoma in the Ontario Cancer Registry between May 1, 1995 and April 30, 1996 (n = 5192). Chart review was performed to obtain detailed tumor, comorbidity, and treatment information. RLE was estimated from a published model derived from a cohort of 451 men with untreated prostate carcinoma who were followed for 15 years. Multivariable logistic regression was performed to evaluate predictors of treatment, such as radical prostatectomy (RP), radiotherapy (RT), or potentially curative therapy (RP or RT), in relation to patient age, comorbidity, tumor characteristics, and RLE. RESULTS: RP was provided within 6 months of diagnosis to 58.7%, 32.1%, 2.6%, and 0% of patients of ages < 60 years, 60-69 years, 70-79 years, and 80+ years, respectively. The results for RT were 6.4%, 30.9%, 23.4%, and 3.3%, respectively. Increasing comorbidity decreased rates of RP but did not affect use of RT. After controlling for comorbidity and tumor characteristics, older men were found to be treated with RP less often than younger men with similar RLE, whereas RLE did not appear to influence receipt of RT. CONCLUSIONS: Although different mechanisms may account for these results, an age bias may be present among urologists and radiation oncologists treating men with localized prostate carcinoma. 相似文献
55.
Jenkins DJ Kendall CW D'Costa MA Jackson CJ Vidgen E Singer W Silverman JA Koumbridis G Honey J Rao AV Fleshner N Klotz L 《The Journal of urology》2003,169(2):507-511
PURPOSE: Herbal remedies high in phytoestrogens have been shown to reduce serum prostate specific antigen (PSA) and have been proposed as a treatment for prostate cancer. Soy proteins used to lower serum cholesterol are rich sources of phytoestrogens. Therefore, we assessed the effect of soy consumption on serum PSA in men who had participated in cholesterol lowering studies. MATERIALS AND METHODS: For 3 to 4 weeks 46 healthy middle-aged men with a range of starting PSA values took soy (mean 44 gm. soy protein daily, 116 mg. isoflavones daily) or control foods, and a subgroup of men took a lower level of soy supplements for 3 months. PSA was measured at the start and end of each treatment. RESULTS: Soy had no significant effect on serum total or free PSA, independent of PSA starting value or isoflavone intake. The lack of effect on PSA was seen, although soy intake was sufficient to reduce low-density lipoprotein cholesterol (5.8 +/- 2.2%, p = 0.012), the estimated coronary heart disease risk (6.1 +/- 2.8% for 10 years, p = 0.032) and the serum concentration of oxidized low-density lipoprotein measured as conjugated dienes (9.5 +/- 3.4%, p = 0.008) in the 3 to 4-week study. In addition, the lack of effect of soy on PSA persisted for the 3 months of the extended study. CONCLUSIONS: At levels of soy intake which reduce low-density lipoprotein cholesterol any potential benefits of soy consumption on prostate cancer are likely to occur for reasons other than alterations in hormone activity. 相似文献
56.
PR Hunziker S Smith M Scherrer-Crosbie N Liel-Cohen RA Levine R Nesbitt SA Benton MH Picard 《Circulation》1999,99(5):1-6
Background--Currently, the reporting and archiving of echocardiographic data suffer from the difficulty of representing heart motion on printable 2-dimensional (2D) media. Methods and Results--We studied the capability of holography to integrate motion into 2D echocardiographic prints. Images of normal human hearts and of a variety of mitral valve function abnormalities (mitral valve prolapse, systolic anterior motion of the mitral leaflets, and obstruction of the mitral valve by a myxoma) were acquired digitally on standard echocardiographic machines. Images were processed into a data format suitable for holographic printing. Angularly multiplexed holograms were then printed on a prototype holographic "laser" printer, with integration of time in vertical parallax, so that heart motion became visible when the hologram was tilted up and down. The resulting holograms displayed the anatomy with the same resolution as the original acquisition and allowed detailed study of valve motion with side-by-side comparison of normal and abnormal findings. Comparison of standard echocardiographic measurements in original echo frames and corresponding hologram views showed an excellent correlation of both methods (P<0.0001, r2=0.979, mean bias=2.76 mm). In this feasibility study, both 2D and 3D holographic images were produced. The equipment needed to view these holograms consists of only a simple point-light source. Conclusions--Holographic representation of myocardial and valve motion from echocardiographic data is feasible and allows the printing on a 2D medium of the complete heart cycle. Combined with the recent development of online holographic printing, this novel technique has the potential to improve reporting, visualization, and archiving of echocardiographic imaging. 相似文献
57.
Gray RE Carroll J Goel Orr Fitch M Chart P Fleshner N Morris BA Greenberg M 《The Canadian journal of urology》1999,6(6):892-897
A sample of family physicians was randomly selected from the membership database of the College of Family Physicians of Canada (CFPC). Potential respondents were mailed a survey questionnaire, and a modified Dillman approach was utilized. A total of 964 completed questionnaires were received, providing a response rate of 50.1%. Although most family physicians were aware of many basic facts about prostate cancer, there were knowledge limitations related to risk factors, relative frequency of the disease (to other cancers), and selected aspects of PSA effectiveness. There was considerable variation in perceived effectiveness of early detection methods, with most physicians taking a conservative approach to PSA utilization. Most family physicians indicated that they have an important role to play in the care of men after they have been diagnosed with prostate cancer. They also expressed a high level of interest in obtaining additional information related to prostate cancer. 相似文献
58.
PR Evans 《Archives of disease in childhood》1977,52(8):664-666
Four hypomelic children of abnormally short stature had slight intellectual defect, melanotic skin, and some facial features in common. 3 were followed to the age of 23-26 years, and they remained small and pigmented. 相似文献
59.
Roberto L. Muller Leah Gerber Daniel M. Moreira Gerald Andriole Jr. Robert J. Hamilton Neil Fleshner J. Kellogg Parsons Stephen J. Freedland 《European urology》2013
Background
Although obesity has been associated with larger prostate volumes (PV), few studies have actually investigated whether obesity enhances PV growth, especially among men using 5α-reductase inhibitors.Objective
To examine whether obesity is associated with enhanced PV growth measured by serial transrectal ultrasound (TRUS) measurements.Design, setting, and participants
We conducted a secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial, which was originally aimed at cancer risk reduction among high-risk men with a single negative prestudy biopsy.Intervention
Per-protocol randomization to placebo or dutasteride and mandatory TRUS-guided biopsies at 2 yr and 4 yr.Outcome measurements and statistical analysis
Percentage change in PV at 2 yr and 4 yr from baseline. We tested its association with baseline body mass index (BMI) groups of <25, 25–29.9, and ≥30 kg/m2 using multivariable linear regression. Secondarily, we tested whether BMI was associated with the likelihood of having no PV reduction among men randomized to dutasteride using multivariable logistic regression.Results and limitations
Of 8122 participants, we analyzed 71.8% and 54.5% with complete 2-yr and 4-yr PV data, respectively. In multivariable analysis, men on placebo with BMI ≥30 versus <25 kg/m2 had enhanced PV growth from baseline (at 2 yr: 17.0% vs 10.7%, p < 0.001; at 4 yr: 29.4% vs 20.1%; p = 0.001). Men on dutasteride with BMI ≥30 versus <25 kg/m2 had attenuated PV reduction from baseline (at 2 yr: −14.3% vs −18.5%; p = 0.002; at 4 yr: −13.2% vs −19.3%; p = 0.001) and higher likelihood of having no PV reduction (at 2 yr: odds ratio [OR]: 1.44; 95% confidence interval [CI], 1.08–1.93; p = 0.014; at 4 yr: OR: 1.62; 95% CI, 1.18–2.22; p = 0.003). We found no significant interactions between BMI and dutasteride on PV change at 2 yr and 4 yr (p interaction ≥0.36). No clinical outcomes or effects of weight change were assessed.Conclusions
Obesity enhanced PV growth and attenuated PV reduction by dutasteride. The null interaction between obesity and dutasteride for PV change implies that the effect of obesity on dutasteride-treated men is likely a combination of dutasteride-driven PV reduction with obesity-driven PV growth rather than decreased dutasteride efficacy.ClinicalTrials.gov identifier
NCT00056407. 相似文献60.